Detalles de la búsqueda
1.
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ann Oncol
; 35(3): 248-266, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307807
2.
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Ann Oncol
; 34(12): 1152-1164, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797734
3.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Ann Oncol
; 33(12): 1250-1268, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36228963
4.
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Ann Oncol
; 32(12): 1590-1596, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34520831
5.
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapyâ.
Ann Oncol
; 32(4): 500-511, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33418062
6.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Ann Oncol
; 31(9): 1216-1222, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32461104
7.
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Breast Cancer Res Treat
; 168(1): 179-187, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29177689
8.
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Breast Cancer Res Treat
; 166(3): 775-785, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28822007
9.
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Gynecol Oncol
; 146(2): 279-284, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28528917
10.
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Ann Oncol
; 27(8): 1525-31, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27177860
11.
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Ann Oncol
; 27(11): 2053-2059, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502721
12.
Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade.
Breast Cancer Res Treat
; 160(3): 491-499, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27744486
13.
A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.
BMC Cancer
; 16: 420, 2016 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27387446
14.
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Ann Oncol
; 22(3): 609-617, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20732932
15.
The role of neoadjuvant chemotherapy in the management of primary breast cancer.
Minerva Ginecol
; 63(3): 261-74, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21654611
16.
FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
Ann Oncol
; 21(8): 1636-1642, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20147743
17.
Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.
Ann Oncol
; 20(11): 1829-35, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19605509
18.
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.
Breast
; 45: 22-28, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30822621
19.
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Ann Oncol
; 19(10): 1698-705, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18477581
20.
Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.
Crit Rev Oncol Hematol
; 99: 81-90, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26712590